Industry

Open Label Outpatient Switch Study Demonstrates Symptom Stability During Transition from Oral Atypical Antipsychotics to Cobenfy™ (xanomeline and trospium chloride)

High treatment completion and no discontinuations due to lack of efficacy observed across faster and slower switch strategies PRINCETON, N.J.–(BUSINESS WIRE)–$BMY #Cobenfy—Bristol Myers Squibb (NYSE: BMY) today announced data from a Phase 4 clinical trial evaluating the symptom stability, safety and tolerability of Cobenfy (xanomeline and trospium chloride) when switching adult outpatients with schizophrenia from … [Read more…]

Lantern Pharma Confirms Panna Sharma Continues to Serve as President and CEO; Alerts Investors to False Third-Party Report

DALLAS–(BUSINESS WIRE)–Lantern Pharma Inc. (NASDAQ: LTRN) (“Lantern” or the “Company”), an AI‑driven, clinical‑stage oncology company leveraging its proprietary RADR® platform to transform the cost and timeline of cancer drug development, today issued the following statement in response to an article published earlier today on an unverified third‑party website. The third‑party article incorrectly claimed that Panna … [Read more…]

Banner|Aetna Brings Community Together for 2026 Phoenix Heart Walk

Arizona health plan continues its longstanding support of cardiovascular research and prevention at the Phoenix Heart Walk PHOENIX–(BUSINESS WIRE)–#Aetna—Banner|Aetna, an Arizona-based health plan offering integrated coverage and care through a partnership between Banner Health and Aetna, a CVS Health company, is participating in the 2026 Phoenix Heart Walk on March 28. Organized by the American … [Read more…]

“Cold-blooded decision on hospital funding,” says CUPE in response to Ford government’s 2026 budget

TORONTO–(BUSINESS WIRE)–The real dollar hospital funding cut announced in the 2026 provincial budget will intensify the crisis in Ontario’s hospitals, which are already funded at the lowest rate in the country, says the Canadian Union of Public Employees. “The government increased hospital funding by four per cent – a real cut of two per cent … [Read more…]

Irenic Sends Letter to Teleflex Board of Directors Regarding Its Refusal to Engage with Potential Acquirors

Demands Openness to Evaluating Credible Opportunities to Maximize Shareholder Value Underscores the Company’s Sustained Value Destruction, Lack of Permanent Leadership, and Board’s Poor Alignment with Shareholders Contends Meaningful Board Change – Including a New Chair – and Engagement of Independent Advisors Capable of Supporting an Objective Evaluation of Strategic Alternatives are Needed NEW YORK–(BUSINESS WIRE)–Irenic … [Read more…]

GenSight Biologics Reports Estimated Full-Year Consolidated Financial Results for 2025

2025 was a turning point with key regulatory milestones providing a solid foundation for 2026. Cash runway is projected to extend through December 2026. Preparation of the Phase III RECOVER study is ongoing, including financing related to the trial. Note: See paragraph on Estimated Full-Year 2025 Consolidated Financial Results at the end of this Press … [Read more…]

Long Bridge Medical Receives Clearance from FDA to Initiate U.S. Pivotal Clinical Study for LensOne Prosthetic Capsular Bag

FDA Approves Initiation of GOLDEN GATE Pivotal Trial Following FDA Breakthrough Device Designation SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Long Bridge Medical, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared initiation of its Investigational Device Exemption (IDE) study for LensOne™, the company’s prosthetic capsular bag designed to enable reliable secondary intraocular lens … [Read more…]

Long Bridge Medical Receives Clearance from FDA to Initiate the U.S. Pivotal Clinical Study for LensOne Prosthetic Capsular Bag

FDA Approves Initiation GOLDEN GATE Pivotal Trial Following FDA Breakthrough Device Designation SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Long Bridge Medical, Inc. today announced that the U.S. Food and Drug Administration (FDA) has cleared initiation of its Investigational Device Exemption (IDE) study for LensOne™, the company’s prosthetic capsular bag designed to enable reliable secondary intraocular lens (IOL) … [Read more…]

Agenus to Host March 2026 Stakeholder Webcast Harnessing the Immune System to Advance BOT + BAL Across Tumor Types and Expand Patient Access

Webcast on Tuesday, March 31, 2026, at 4:30 p.m. ET LEXINGTON, Mass.–(BUSINESS WIRE)–$AGEN #BAL—Agenus Inc. (“Agenus”) (Nasdaq: AGEN), a leader in immuno-oncology, today announced it will host its March Stakeholder Webcast focused on continued progress of its botensilimab and balstilimab (BOT+BAL) immunotherapy program and will provide an update on the Company’s patient access programs, development … [Read more…]

Chronilogix Announces Dr. Geoffrey Williams’ Appointment to Advisory Committee, Supporting Expansion into AI-Driven Mental Health Coaching

PALM BEACH GARDENS, Fla.–(BUSINESS WIRE)–Chronilogix, an AI digital health company transforming access, delivery, and cost of chronic care coaching, today announced that Dr. Geoffrey Williams has joined its Advisory Committee. Dr. Williams’ appointment coincides with Chronilogix’s expansion to include a dedicated AI-powered mental health module, further strengthening the company’s mission to deliver affordable, always-available coaching … [Read more…]